Melanoma

March 24, 2022

Ongoing Trial: The BAMM2 trial (EA6191) explores adding the drug hydroxychloroquine to standard treatment for certain patients with melanoma that has progressed after immunotherapy

This study is evaluating the effect of adding hydroxychloroquine to the usual treatment for patients with advanced, BRAF-mutant melanoma